Navigation Links
Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
Date:5/1/2012

SUNNYVALE, Calif., May 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to present in the Emerging Companies Showcase at the New York Biotechnology Association's 21st Annual Meeting on May 2nd, 2012 in New York City at the Marriott Marquis Hotel. Mr. Commissiong will be hosting individual investor meetings following the presentation.

EVENT INFORMATION AT A GLANCE:WHO:

Gerald Commissiong, President and Chief Executive OfficerWHEN:

May 2nd, 2012 @ 2:30pm in the Lyceum RoomWHERE:

Marriott Marquis Hotel, 1535 Broadway, New York City, NYLIVE WEBCAST:

http://www.onemedplace.comAbout MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease.  The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line.
It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc. Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. For further information please visit http://www.Amarantus.com .

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

 

MEDIA CONTACTS:
Amarantus Biosciences, Inc.
Gerald Commissiong
pr@amarantus.com
408.737.2734

 


'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences Reports Addition of New Scientific Articles to MANF Publications List
2. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
3. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
7. Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
8. Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating!
9. Celling Biosciences Sponsors 7th Annual Stem Cell Summit
10. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
11. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:7/31/2017)... Tru-D SmartUVC robots have arrived at Brian Allgood Army Community ... for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing robot that is ... cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army hospitals ... "Although the BAACH has a very low infection rate, below national ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS ... recently the availability of a new professional fee E/M leveling calculator tool. The ... to the healthcare industry. E/M coding is complex which supports the need for ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of child abuse and neglect, and the struggles faced while hoping for a ... creation of published author, Judy Von Bernewitz, who spent 13 years working with ...
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional confusion. ... up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar with ... to his life, he noticed immediately that opportunities and blessings began to shift in ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... addition of two plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, ... who have successfully completed residency in Plastic and Reconstructive Surgery. The candidate ...
Breaking Medicine News(10 mins):